Results 141 to 150 of about 7,703 (180)

Lymphography in the diagnosis of non‐seminoma tumours of the testis

Journal of Surgical Oncology, 1982
AbstractIn a series of 86 lymphograms correlated to histological findings after retroperitoneal lymph node dissection or to laparotomy findings, reliability proved to be 78%. The reliability of lymphograms evaluated as positive was 88%, while that of negative lymphograms was 74%.
Wobbes, T., Blom, J.M.H., Oldhoff, J., Schraffordt Koops, H   +3 more
openaire   +3 more sources

Surgery versus surveillance in stage I non-seminoma testicular cancer

Seminars in Surgical Oncology, 1999
Today, the standard treatment for patients with clinical Stage I non-seminomatous testicular germ cell tumors (NSTGCT) following orchidectomy is either primary retroperitoneal lymph node dissection (RPLND) or close surveillance with cisplatin-based polychemotherapy in case of a relapse. Both treatment modalities provide excellent overall survival rates
D J, Sonneveld, H S, Koops, D T, Sleijfer, H J, Hoekstra   +3 more
openaire   +4 more sources

Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis

Clinical Oncology, 1991
Seventy-Two patients with stage I testicular non-seminoma presenting between January 1984 and December 1988 were managed either by adjuvant chemotherapy in the presence of histological adverse prognostic factors or by surveillance if none of these factors were present.
G, Madej, A, Pawinski
openaire   +2 more sources

Increasing the Dose Intensity of Chemotherapy in Poor-Prognosis Metastatic Non-Seminoma

European Urology, 1993
The overall cure rate of patients with metastatic non-seminoma of the testis is high and a recent survey of 795 patients by the Medical Research Council indicated that 85% were alive 3 years after the start of chemotherapy. Two major categories of patients can be identified with a poorer prognosis.
A, Horwich, C, Wilson, P, Cornes, J, Gildersleve, D, Dearnaley   +4 more
openaire   +2 more sources

Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer

European Journal of Cancer, 1997
250 patients with clinical stage 1 non-seminomatous germ cell tumours of the testis (NSGCT 1) were included into a prospective multicentre protocol during 1990-1994 and treated according to three risk strata: patients without tumour cell invasion of vascular structures in the testis (VASC-) and elevated serum AFP levels (AFP+) at orchiectomy were ...
O, Klepp, O, Dahl, P, Flodgren, U, Stierner, A M, Olsson, J, Oldbring, S, Nilsson, L, Daehlin, M, Tørnblom, R, Småland, H, Starkhammar, L, Abramsson, E, Wist, N, Raabe, T, Edekling, E, Cavallin-Ståhl   +15 more
openaire   +2 more sources

[Chemotherapy of non-seminoma tumours of the testis (author's transl)].

La Nouvelle presse medicale, 1981
During the past few years considerable progress has been achieved in the treatment of non-seminoma tumours of the testis, particularly since cisplatin was introduced. The use of this new drug in combination with other chemotherapeutic agents has resulted in complete remission in over 50% of all advanced cases, and many such remissions that have now ...
R, Abele, M, Rozencweig
openaire   +1 more source

Metastatic Seminoma: Should Treatment Be Different from Non-seminoma?

2002
It is now more than 50 years since Friedman [1] first demonstrated that seminoma was more sensitive to radiation than non-seminoma and it has since been standard to give a different radiation dosage. In contrast, although our group first demonstrated 18 years ago that the chemosensitivity of metastatic seminoma to single agent cisplatin was so ...
J. Ong, R. T. D. Oliver, J. Shamash, M. Williams, B. Sizer, J. Ostrowski, J. Le Vay   +6 more
openaire   +1 more source

Minimizing Morbidity from Surgery for Non-seminoma Testicular Cancer

2002
Most patients with testis cancer are now cured. Efforts to improve treatment are therefore primarily directed to reducing morbidity while maintaining the excellent survival rate. The urological surgical aspects of treatment include the management of the primary tumour as well as retroperitoneal metastases. The concept of scrotal violation, the role for
M. A. S. Jewett, B. Shekarriz, A. Grabowski   +2 more
openaire   +1 more source

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology, 2022
M A Climent, Gedske Daugaard, H S Haugnes   +2 more
exaly  

[Is risk-oriented therapy in stage I non-seminoma tumor advisable?].

Der Urologe. Ausg. A, 1993
For a long time the usual regimen for patients with a non-seminomatous testicular tumor, clinical stage I, was an orchiectomy and retroperitoneal lymphadenectomy. Because of the possible loss of ejaculation as a aggravating consequence for the patient, one must think about alternatives. One of those is the wait-and-see strategy.
S, Krege, H, Rübben
openaire   +1 more source